Assess the Efficacy and Safety of Emerging Strategies That Impact Brain Cholesterol Turnover

Link to CME: Claim Credit - https://bit.ly/3OByCaE

In this episode, Drs. Halford and Hahn discuss the current treatment landscape of developmental and epileptic encephalopathies (DEEs), such as Lennox-Gastaut syndrome and Dravet syndrome, and the emerging role of brain cholesterol in addressing seizure frequency. The full episode covers:

• How to diagnose these epilepsies and the FDA-approved treatment options in the first-line and second-line settings
• The role of antiseizure medications in DEE treatment management
• The nonpharmacological treatment options available to patients with DEEs
• The emerging role of brain cholesterol in neurologic diseases like DEEs and Alzheimer’s disease
• Results from the ELEKTRA clinical trial, including cholesterol synthase inhibitors’ impact on seizure frequency
• The future of soticlestat as a treatment option for pediatric patients with DEEs

Presenters:

Jonathan J. Halford, MDProfessorDirector, Translational Research UnitDepartment of NeurologyMedical University of South CarolinaCharleston, SC

Cecil Hahn, MD, MPH, FRCPCProfessorPediatric EpileptologistUniversity of TorontoToronto, Ontario, Canada

Content based on an online CME program supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Link to full program: https://bit.ly/45UUpQy